NASDAQ:AKRX

Akorn Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range
$0.09
$0.32
52-Week Range N/A
Volume1.19 million shs
Average Volume9.60 million shs
Market Capitalization$3.60 million
P/E RatioN/A
Dividend YieldN/A
Beta0.95

Receive AKRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Akorn and its competitors with MarketBeat's FREE daily newsletter.


Akorn logo

About Akorn

Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.83 out of 5 stars

Medical Sector

1231st out of 2,100 stocks

Pharmaceutical Preparations Industry

561st out of 832 stocks

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Akorn (NASDAQ:AKRX) Frequently Asked Questions

What stocks does MarketBeat like better than Akorn?

Wall Street analysts have given Akorn a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Akorn wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Akorn's earnings last quarter?

Akorn, Inc. (NASDAQ:AKRX) released its earnings results on Monday, May, 11th. The company reported $0.36 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.45. The company had revenue of $204.69 million for the quarter, compared to analyst estimates of $168.90 million. Akorn had a negative net margin of 55.64% and a positive trailing twelve-month return on equity of 8.53%.
View Akorn's earnings history
.

Who are Akorn's key executives?

Akorn's management team includes the following people:
  • Mr. Duane A. Portwood, Exec. VP & CFO (Age 53)
  • Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Jonathan Kafer, Exec. VP & Chief Commercial Officer (Age 56)
  • Dr. Bruce Kutinsky, Consultant (Age 53)
  • Mr. Douglas S. Boothe, Pres, CEO & Direcor (Age 55)

Who are some of Akorn's key competitors?

What other stocks do shareholders of Akorn own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include (CELG), Integrated Device Technology (IDTI), Skechers U.S.A. (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Square (SQ).

What is Akorn's stock symbol?

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

How much money does Akorn make?

Akorn has a market capitalization of $0.00 and generates $682.43 million in revenue each year. The company earns $-226,770,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.

How many employees does Akorn have?

Akorn employs 2,227 workers across the globe.

What is Akorn's official website?

The official website for Akorn is www.akorn.com.

Where are Akorn's headquarters?

Akorn is headquartered at 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045.

How can I contact Akorn?

Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]


This page was last updated on 6/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.